A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Evolocumab (Primary)
- Indications Cardiovascular disorders; Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Myocardial infarction; Stroke
- Focus Adverse reactions
- Sponsors Amgen
- 09 Jun 2017 Planned End Date changed from 1 Oct 2021 to 29 Sep 2021.
- 09 Jun 2017 Planned primary completion date changed from 1 Oct 2021 to 29 Sep 2021.
- 12 Dec 2016 Status changed from recruiting to active, no longer recruiting.